Get the Stockscreener App
324.39
0.59%
-1.92
After Hours:
324.85
0.46
+0.14%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $324.39, with a volume of 2.03M.
It is down -0.59% in the last 24 hours and down -8.70% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$326.31
Open:
$325.545
24h Volume:
2.03M
Relative Volume:
0.78
Market Cap:
$175.17B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
22.56
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-1.58%
1M Performance:
-8.70%
6M Performance:
-5.70%
1Y Performance:
+19.08%
1-Day Range:
$321.21
$325.77
1-Week Range:
$321.21
$338.49
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
324.39 | 176.21B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
988.09 | 896.13B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.92 | 545.74B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
209.41 | 371.72B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.92 | 281.60B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.15 | 282.55B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Eli Lilly Stock: Next Stop $2,000? - The Motley Fool
Gout: A type of inflammatory arthritis that may be tricky to diagnose - WJAR
Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism - Insider Monkey
Amgen Japanese Partner Urges Caution On Tavneos Use - Benzinga
Amgen Inc. stock (US0311621009): focus on Horizon integration and latest quarterly results - AD HOC NEWS
ChemoCentryx to Pay $69 Million to End Investor Lawsuit (1) - Bloomberg Law News
Amgen stock (US0311621009): obesity deal and recent approvals keep pipeline in focus - AD HOC NEWS
Amgen Stock Analysis: Repatha Surges 34% But Tax Litigation Clouds the Return Case. Here’s What to Expect - TIKR.com
TD Private Client Wealth LLC Sells 3,426 Shares of Amgen Inc. $AMGN - MarketBeat
Intratumoral Cancer Therapies Market is expected to Hit US$ - openPR.com
North Dakota State Investment Board Makes New Investment in Amgen Inc. $AMGN - MarketBeat
GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): earnings beat, dividend and guidance keep biotech giant in focus - AD HOC NEWS
Amgen Inc. $AMGN Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Leuthold Group LLC Buys 4,396 Shares of Amgen Inc. $AMGN - MarketBeat
L & S Advisors Inc Takes Position in Amgen Inc. $AMGN - MarketBeat
iA Global Asset Management Inc. Raises Position in Amgen Inc. $AMGN - MarketBeat
STF Management LP Sells 5,198 Shares of Amgen Inc. $AMGN - MarketBeat
Northwestern Mutual Wealth Management Co. Acquires 323,064 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Canada Post Corp Registered Pension Plan - MarketBeat
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Amgen Inc stock (US0311621009): lungs cancer setback meets steady biotech cash flow - AD HOC NEWS
Japan Flags 20 Deaths, Liver Injury Risk in Amgen's Rare Disease Drug Tavneos - Medical Dialogues
Amgen Inc. stock (US0311621009): focus on latest earnings and drug pipeline developments - AD HOC NEWS
Amgen (AMGN) Faces Scrutiny After Deaths Linked to Tavneos Thera - GuruFocus
Amgen’s Tavneos linked to 20 deaths in Japan (AMGN:NASDAQ) - Seeking Alpha
Stephens Inc. AR Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MSN
Is trending stock Amgen Inc. (AMGN) a buy now? - MSN
Commerzbank Aktiengesellschaft FI Has $48.62 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 3,513 Shares of Amgen Inc. $AMGN - MarketBeat
Applied Finance Capital Management LLC Acquires 3,069 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s Tavneos discouraged by Japanese partner after deaths - The Japan Times
Amgen’s rare disease drug linked to deaths, liver injuries in Japan, Kissei reports - WKZO
20 People in Japan Died After Taking Amgen Drug - WSJ
Amgen’s Tavneos Discouraged by Japanese Partner After Deaths - Bloomberg.com
Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports - Reuters
Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ - Moomoo
Amgen stock falls after Kissei warns on Tavneos liver risks By Investing.com - Investing.com Nigeria
Amgen stock falls after Kissei warns on Tavneos liver risks - Investing.com
Amgen Inc. stock (US0311621009): focus on Repatha growth as first-quarter 2026 results mix - AD HOC NEWS
Amgen Inc. (AMGN) is a trending stock: Facts to know before betting on it - MSN
Amgen Expands Data Demands From Providers Getting Drug Discounts - Bloomberg Law News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Amgen Inc. $AMGN Stock Holdings Lessened by Thrivent Financial for Lutherans - MarketBeat
Conning Inc. Acquires 97,957 Shares of Amgen Inc. $AMGN - MarketBeat
Arbejdsmarkedets Tillaegspension Invests $24.26 Million in Amgen Inc. $AMGN - MarketBeat
Amgen Leaders Discuss the Future of Health at Milken 2026 - Amgen
FDA Approval for WEZLANA issued to AMGEN INC - Quantisnow
Amgen stock (US0311621009): weight-loss hopes and Prolia boost after Q1 numbers - AD HOC NEWS
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains - Yahoo Finance
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):